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I was born in Haderup in Central Jutland in 1987, lived in Aasiaat, Greenland from 
1989-1993, and then moved to Fjerritslev in Northern Jutland where I grew up and 
graduated from high school.  
In 2008 I began my studies for a bachelor’s degree in Medicine with Industrial 
Specialisation. In 2013 I graduated from Aalborg University with a master’s degree 
in Medicine with Industrial Specialisation, with specialisation in Translational 
Medicine. During the last two years of my master’s education, I took part in a 
randomised controlled trial of vitamin D for the treatment of migraine. I was 
instrumental in planning the study, gaining approval from the Regional Research 
Ethics Committee, patient recruitment, and execution of all study-related procedures. 
The education in Medicine with Industrial Specialisation and its focus on gaining 
practical experience with the complexity of performing clinical trials sparked my 
interest in clinical research. When the opportunity then arose for me to conduct this 
PhD study, which is focused on bone imaging in prostate cancer I began as a PhD 
student at the department of Nuclear Medicine, Aalborg University Hospital, in 
September 2013. 
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PREFACE 
This PhD thesis is based on clinical studies performed in the department of Nuclear 
Medicine, Aalborg University Hospital, in collaboration with the Department of 
Urology, Aalborg University Hospital, and the Department of Nuclear Medicine and 
the Department of Urology, Regional Hospital West Jutland Herning and Holstebro. 
Over the course of this PhD study, some changes had to be implemented due to 
unforeseen challenges. First, this was intended to be a single, large, prospective, 
multicentre diagnostic test accuracy study of nuclear medicine bone imaging 
modalities in prostate cancer, with more than 100 patients included. Within the first 
year of the study, me and my supervisors realised that it was not possible to 
accomplish this within a realistic timeframe. Therefore, we planned two additional 
studies, which focused on observer agreement and monitoring of bone metastases in 
prostate cancer based on the same imaging modalities. This PhD thesis is thus based 
on three studies that focused on bone imaging in prostate cancer with different aims, 
outcomes and perspectives.  
Financial support was generously provided by the North Denmark Region Research 
Foundation, the Danish Medical Research Grant/the Højmosegaard Grant, the 
Heinrich Kopps Grant, the Obel Family Foundation, and Aalborg University 
Hospital.  
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ENGLISH SUMMARY 
Prostate cancer is one of the most common cancers in men worldwide. Prostate cancer 
often presents indolent tumours with little or no lethal potential, and patients may die 
from other causes. Some patients have aggressive prostate cancer that evolves 
quickly and is associated with increased morbidity and early death. A major 
complication in advanced prostate cancer is bone metastases, which can cause pain, 
pathological fractures, and compression of spinal nerves resulting in severe pain 
radiating to the extremities and possibly sensory and motor disturbances. 
Treatment of prostate cancer can roughly be divided into treatment with curative 
intent and palliative, life-sustaining treatment. In patients with a high risk of 
metastases, treatment is limited to palliative, life-sustaining therapies. Therefore, 
accurate methods for the detection of bone metastases are essential. Clinical 
guidelines recommend using planar whole-body bone scan (BS) for the diagnosis and 
monitoring of bone metastases. This method uses a radioactive tracer to visualise the 
skeleton and possible changes. It is a sensitive, but not particularly specific method, 
as it also detects benign bone disorders.  
Technical advances such as single-photon emission computed tomography/computed 
tomography (SPECT/CT), which allows for tomographic image acquisition and CT 
for attenuation correction and anatomical co-localisation have emerged since the 
introduction of BS. The use of positron emission tomography/CT (PET/CT) scanners 
has also increased in the past decade, including the use of bone PET/CT with 
18F-sodium-fluoride (NaF), which, like the BS, is able to visualise the skeleton and 
possible changes. NaF PET/CT is associated with higher tracer uptake, increased 
target-to-background ratio and the higher spatial resolution of PET. However, these 
newer technologies have not been adopted in clinical guidelines because of the lack 
of clear-cut evidence that these methods improve the diagnosis of bone metastases. 
Study I of this PhD was a prospective study, which was in complete compliance with 
recommendations for diagnostic test accuracy studies. This study was conducted to 
compare the diagnostic performance of BS, SPECT/CT and NaF PET/CT in prostate 
cancer patients at high risk of bone metastases and the results showed that there was 
no statistically significant difference between the three modalities. SPECT/CT and 
NaF PET/CT demonstrated an apparent improved sensitivity, while the specificity 
was comparable across the three modalities. Thus, SPECT/CT and NaF PET/CT can 
be used for the detection of bone metastases and should be included in clinical 
guidelines.  
Another important aspect of prostate cancer management is the monitoring of 
treatment responses; for bone metastases, this is also done using BS. Bone response 
monitoring is not uniform, and several methods and approaches are employed. 
VIII 
 
Furthermore, response classification might be associated with inter-observer 
variations. Therefore, Study II of the PhD investigated inter-observer agreement for 
evaluation of treatment responses in bone on BS for three different methods for 
classification of response. Considerable variation in observer agreement was 
observed depending on the method being used. Stringent criteria that distinguish only 
progression (appearance of two or more new bone metastases) vs non-progression 
demonstrated an almost perfect agreement (Prostate Cancer Working Group 2 – 
PCWG-2 criteria). Only moderate agreement was found when using more subjective 
methods that take into account the degree of response (MD Anderson criteria and 
standard clinical assessment). Therefore, the use of strict criteria such as PCWG for 
the evaluation of treatment responses in bone is recommended.  
No studies have investigated the use of NaF PET/CT vs BS to assess treatment 
responses in bone. In Study III of the PhD, which was a prospective exploratory 
study, no significant difference between NaF PET/CT and BS was found when using 
the PCWG criteria for treatment response assessment. However, a trend was observed 
that with more advanced prostate cancer stages, agreement between these two 
modalities decreased. With evidence showing that progression on BS is correlated 
with impaired survival, our results indicate that further studies on the use of 
NaF PET/CT for treatment response monitoring are necessary before this can be 
recommended as equal to bone scan.  
In conclusion, this PhD study demonstrated that SPECT/CT and NaF PET/CT can be 
considered as equal to BS for the diagnosis of bone metastases and that these 
modalities should be adopted in clinical guidelines for this purpose. When monitoring 
treatment responses in bone, the use of strict criteria, such as the PCWG criteria, in 
both clinical trials as well as in daily clinical situations, is recommended. 
NaF PET/CT for treatment response monitoring in bone should be investigated more 
fully, especially with a focus on whether the use of NaF PET/CT is associated with 
improved patient outcome. 
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DANSK RESUMÉ 
Globalt er prostatakræft er en af de hyppigste kræftformer hos mænd. Prostatakræft 
er ofte et fredeligt forløb uden dødelig udgang. Dog har nogle patienter en aggressiv 
prostatakræft som vokser hurtigt, forårsager komplikationer og for tidlig død. 
Knoglemetastaser, som kan være svært invaliderende, er en af de største 
komplikationer ved prostatakræft og det kan lede til knoglesmerter og patologiske 
frakturer. Knoglemetastaser i rygsøjlen kan give rygsmerter og føre til afklemning af 
nerverne  i rygmarven med svære smerter, der stråler ud i arme og ben, 
føleforstyrrelser og evt. lammelser til følge.  
Behandling af prostatakræft kan overordnet inddeles i kurativt intenderet behandling 
og palliativ, livsforlængende behandling. Hos patienter med høj risiko for spredning 
af kræft gives i reglen kun palliativ, livsforlængende behandling. Derfor er gode og 
præcise metoder til at detektere spredning af prostatakræft essentielle. Rutinemæssigt 
anvendes knogleskintigrafi til påvisning og monitorering af knoglemetastaser. Her  
visualiseres skelettet og eventuelle forandringer vha. et radioaktivt sporstof. 
Undersøgelsen har en høj sensitivitet, men er relativt uspecifik da den også viser 
benigne knoglelidelser, gamle frakturer mm. 
I de seneste årtier er der sket en udvikling af scannere, f.eks. SPECT/CT som giver 
mulighed for tomografiske billeder, og fusionering med CT til attenuationskorrektion 
og lokalisationsbestemmelse. Brugen af PET/CT scannere er desuden steget 
betydeligt, herunder også knogle-PET/CT, hvor sporstoffet 18F-natrium fluorid (NaF) 
bruges til at visualisere forandringer i skelettet som ved knogleskintigrafien. I forhold 
til knogleskintigrafi har NaF PET/CT en højere billedopløsning, optaget af 
sporstoffet i knoglerne er større og der er et bedre signal-støj-forhold. Til trods for 
den teknologiske udvikling er det fortsat knogleskintigrafi der anbefales i kliniske 
vejledninger. Grundlaget for dette er, at der ikke foreligger klar evidens for, at de nye 
metoder forbedrer diagnosen af knoglemetastaser. 
Studie I i denne PhD var et metodologisk velfunderet, prospektivt studie der fulgte 
retningslinjerne for diagnostiske akuratesse studier. Heri blev de diagnostiske 
egenskaber for knogleskintigrafi, SPECT/CT og NaF PET/CT sammenlignet  hos en 
gruppe prostatekræftpatienter med høj risiko for knoglemetastaser. Der blev ikke 
fundet nogen signifikant forskel mellem de tre metoder. Tilsyneladende var 
sensitivitet højere for både SPECT/CT og NaF PET/CT end for knogleskintigrafi, 
mens specificiteten var sammenlignelig metoderne imellem. Disse nyere metoder kan 
dermed anvendes på lige fod med knogleskintigrafi og bør derfor inkluderes i kliniske 
vejledninger.  
Et andet vigtigt element i behandling af prostatakræft er monitorering af 
behandlingseffekt. Traditionelt bruges også her knogleskintigrafi. Vurdering af 
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behandlingsrespons er ikke ensartet, og der anvendes forskellige metoder og tilgange. 
Desuden kan der være variation i klassifikation af respons mellem forskellige 
observatører. Studie II i denne PhD undersøgte observatørvariationen ved vurdering 
af behandlingsrespons på knogleskintigrafi for tre forskellige metoder til at 
klassificere respons. Der sås betydelig forskel i overensstemmelsen mellem 
observatørerne afhængigt af hvilken metode der blev anvendt til klassificering af 
respons. Ved brugen af meget stringente kriterier (Prostate Cancer Working Group 2, 
PCWG-2 kriterier), hvor der kun skelnes mellem progression (minimum to nye 
knoglemetastaser) eller ej, var overensstemmelsen meget god. Ved mere subjektive 
metoder hvor graden af respons angives (MD Anderson kriterier og rutinemæssig 
klinisk vurdering) var overensstemmelsen mellem observatørene kun moderat.  
Brugen af stringente kriterier, gerne PCWG, til vurdering af behandlingsrespons i 
knogler anbefales derfor både til klinisk brug og til brug i kliniske studier.  
Ud over hvilke metoder der skal bruges til at vurdere behandlingsrespons ved 
knoglemetastaser, er der ingen studier der direkte har sammenlignet NaF PET/CT og 
knogleskintigrafi ved monitorering af behandlingseffekt om end begge 
undersøgelsesmetoder anvendes. I studie III i denne PhD blev overenstemmelsen 
mellem knogleskintigrafi og NaF PET/CT til klassificering af respons vha. PCWG-2 
kriterierne undersøgt. Det var et prospektivt, eskplorativt studie der involverede 
prostatakræft patienter der var under forskellige behandlinger og sygdomsstadier. 
Der var ingen signifikante forskelle mellem de to metoder, men der var en tendens 
til, at man med knogleskintigrafi fandt progression hos flere patienter og/eller på et 
tidligere tidspunkt end med NaF PET/CT. Denne tendens blev mere udtalt ved sene 
sygdomsstadier. Man har set, at der ved progression på knogleskintigrafi er 
korrelation til dårligere overlevelse. Derfor indbyder resultaterne til, at NaF PET/CT 
undersøges nærmere til vurdering af behandlingsrespons ved prostatekræft patienter 
med knoglemetastaser, før denne metode kan anbefales på lige fod med 
knogleskintigrafi. 
Afslutningsvist har resultaterne af denne PhD vist, at NaF PET/CT og SPECT/CT 
kan bruges, og bør anbefales, på lige fod med knogleskintigrafi, til detektering af 
knoglemetastaser ved prostatakræft. Ved evaluaering af behandlingseffekt bør der 
som udgangspunkt anvendes stringente kriterier, som PCWG, for at give de mest 
konsekvente besvarelser både i klinikken og i kliniske studier. Brugen af 
NaF PET/CT til vurdering af behandlingseffekt bør undersøges nærmere, særligt i 
forhold til om resultaterne af NaF PET/CT scanning bidrager til forbedret 
patientforløb. 
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CHAPTER 1. INTRODUCTION 
 EPIDEMIOLOGY 
Prostate cancer (PCa) is the second most frequent cancer in men worldwide (1, 2). 
During the past decade, the incidence of PCa has shifted substantially. An increase in 
regular testing of prostate-specific antigen (PSA) resulted in a dramatic increase in 
PCa incidence until approximately 2009, while the mortality remained stable. It was 
later recognised that regular PSA screening resulted in detection of a large proportion 
of latent and asymptomatic PCa that would never become clinically significant. Thus, 
regular PSA screening has since decreased and the incidence of PCa has consequently 
decreased or stabilised in most countries, including Denmark. This has not affected 
mortality (1, 3, 4). 
 STAGING 
Prostate cancer is diagnosed either by opportunistic PSA testing or by PSA testing in 
the setting of lower urinary tract symptoms, e.g., urgency, frequency, incomplete 
bladder emptying. A definitive diagnosis is based on histopathological verification 
from transrectal ultrasound-guided biopsies from the prostate or from post-operative 
histopathology (5-7). The standard for grading of PCa is the Gleason grading system 
in which histopathological patterns of the tumour specimens are assessed and assigned 
a score. The Gleason score is the sum of the scores of the two most frequent patterns 
found in the tumour specimens, where a higher score is associated with a more 
aggressive cancer and worse prognosis (8). 
Prostate cancer is classified and staged according to the TNM staging system for 
malignant tumours (9). T-staging is based on the primary tumour: T1) a non-palpable 
tumour that can be detected by biopsies; T2) the tumour is palpable, but confined in 
within the prostate; T3) the tumour has extended through the prostatic capsule; and 
T4) the tumour has invaded adjacent structures. N-staging determines the involvement 
of regional lymph nodes, and M-staging identifies the presence of distant metastases, 
distinguishing between non-regional lymph nodes, bone, and other sites (9). 
Prostate cancer patients are risk-stratified according to their risk of biochemical 
recurrence following treatment with curative intent, i.e., radical prostatectomy or 
external beam radiation; see Table 1 for risk classifications according to clinical 
guidelines (5-7). The current PhD thesis studied only high-risk and advanced PCa 
patients who were not eligible for treatment with curative intent.  
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Table 1 Risk stratification according to clinical guidelines 
 Low-risk Intermediate-risk High-risk 
EAU (5) PSA < 10 ng/mL 
and GS < 7 
and cT1-2a 
PSA 10-20 ng/mL 
or GS 7  
or cT2b 
PSA > 20 
or GS > 7 
or cT2c 
NCCN (6) PSA < 10 ng/mL 
GS ≤ 6 
T1-T2a 
PSA 10-20 ng/mL 
or GS 7  
or T2b-T2c 
PSA >20 ng/mL 
or GS 8-10 
or T3a  
AUA (7) PSA ≤ 10 ng/mL 
and GS ≤ 6  
and cT1c-T2a 
PSA 10-20 ng/mL 
or GS 7  
or cT2b  
PSA > 20 ng/mL 
or GS 8-10 
or cT2c 
EAU, European Association of Urology; NCCN, National Comprehensive 
Cancer Network; AUA, American Association of Urology; PSA, prostate 
specific antigen; GS, Gleason Score 
 BONE METASTASES 
In many cases, PCa is associated with clinically indolent tumours that have little or 
no lethal potential. However, some patients present with more aggressive PCa that 
grows quickly and spreads to other parts of the body, resulting in increased morbidity 
and early death. Bone metastases are common in advanced PCa and cause severe 
morbidity for the affected patients, including bone pain, vertebral collapse, 
pathological fractures, and spinal cord compression (10-12). A large proportion of 
patients show bone metastases post-mortem (13). It was previously shown that 7.7% 
of newly diagnosed PCa patients have or will develop bone metastases within the first 
year post-diagnosis (14). A recent Danish study showed that in a population of newly 
diagnosed PCa patients, approximately 13% had bone metastases at the time of 
diagnosis regardless of stage (15), and unexplained bone pain was found to be a 
predictor of bone metastases in this patient population (16).  
Detection of bone metastases is essential in the management of PCa, as treatment with 
curative intent is only indicated in patients with local or locally advanced PCa, while 
patients with advanced PCa are treated with palliative, life-sustaining therapies only. 
Clinical guidelines recommend bone metastases staging in patients with 
intermediate- and high-risk PCa by planar whole-body bone scan (BS), and they agree 
that staging is unnecessary in low-risk PCa patients (Table 1) (5-7).  This is supported 
by studies showing that BS is redundant in the majority of patients with low- to 
intermediate-risk PCa (15, 17, 18). However, despite the lack of evidence showing 
improved detection or survival, imaging-based staging of low-risk PCa patients is 
often routinely performed. For this reason, the American Society of Oncology 
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identified staging of bone metastases in PCa as number two of five major 
opportunities to reduce costs and improve care within oncology (19). 
 SYSTEMIC TREATMENT OF PROSTATE CANCER 
Treatment of PCa depends on the clinical disease state, which can roughly be divided 
into treatment of localised disease with curative intent, or palliative, life-sustaining 
therapies. Treatment of incurable PCa depends on the clinical disease state of 
advanced PCa (Figure 1) i.e., non-metastatic clinically localised PCa, metastatic 
hormone-sensitive PCa, and nonmetastatic (nm) or metastatic (m) castration-resistant 
prostate cancer (CRPC). An overview of the most commonly used treatment options 
in Denmark is shown in Figure 1, and the options are briefly described below. 
1.4.1. ANDROGEN-DEPRIVATION THERAPY 
Androgens promote the growth of normal prostate cells, and initially, androgens are 
necessary for the growth of PCa by stimulating the proliferation of PCa cells. 
Therefore, androgen-deprivation therapy (ADT) remains the primary treatment for 
incurable patients with androgen-dependent PCa (20). Androgen-deprivation therapy 
involves a complete elimination or blockage of androgens. The most common 
therapies include surgical removal of the androgen-producing glands (the testes) by 
bilateral orchiectomy, inhibition of gonadotropin-secretion by luteinising 
hormone-releasing hormone (LHRH) agonists or antagonists, or by blocking 
androgen receptors with steroid or non-steroid anti-androgens. Most of these 
treatments affect libido.  
Surgical castration is a simple but irreversible procedure. It is the fastest and easiest 
way to achieve castration levels of testosterone (< 50 ng/mL), and it is considered the 
“gold standard” of ADT (11).  
Luteinising hormone-releasing hormone agonists initially interact with LHRH 
receptors and stimulate the production of luteinising hormone (LH), which causes an 
initial flare response with increased androgen production lasting for a few weeks. The 
LHRH receptors are then downregulated as the pituitary gland is desensitised, which 
leads to a decrease in androgen production in the testes. Blood levels of testosterone 
decrease to castration levels within 2-4 weeks (21, 22). A meta-analysis found that 
there is no significant difference in overall survival (OS) (p>0.2) and progression-free 
survival (PFS) between treatment with LHRH agonists and orchiectomy (23). 
Androgen blockade by LHRH agonists can be reversible and might therefore be 
preferred. Because of the initial flare response, treatment with LHRH agonists is often 
combined with anti-androgen therapy initially for complete androgen blockage (11).  
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.  Inspired by (24). 
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Luteinising hormone-releasing hormone antagonists block the LHRH receptors, thus 
blocking the release of LH. This causes an almost instant decrease in testosterone, and 
patients reach castration levels within a few days, i.e., there is no flare reaction. 
Studies have found that the most commonly used LHRH antagonist, Degarelix, is 
non-inferior in relation to OS and PSA PFS compared with LHRH agonists (25).  
Steroid anti-androgens act by blocking the androgen receptors and by supressing 
androgen production. Non-steroidal anti-androgens act solely by blocking the 
androgen receptors. Most often, anti-androgens are used in combination with LHRH 
agonists. Anti-androgen monotherapy is associated with reduced OS and PFS and is 
rarely used. In many cases, the libido is preserved when using anti-androgens as 
monotherapy, which is the most common rationale behind anti-androgen 
monotherapy (26, 27).  
1.4.2. NEXT-GENERATION HORMONAL THERAPY 
Initial treatment with ADT leads to a decrease in PSA and clinical improvement. In 
the majority of patients, however, the cancer inevitably becomes castration-resistant, 
and it is estimated that 10-20% of PCa patients develop CRPC within five years (28). 
The definition of CRPC is serum castration levels of testosterone and confirmed PSA 
progression or progression of osseous or soft-tissue metastases (11). Treatment of 
CRPC has evolved significantly in recent years with the introduction of highly 
effective novel therapies. 
Abiraterone acetate is an androgen synthesis inhibitor. It inhibits both testicular 
androgen synthesis and extra-gonadal androgen synthesis. Abiraterone has been 
shown to have a significant effect on OS in chemotherapy naïve men with mCRPC 
(34.7 vs 30.2 months for placebo, p=0.0033) (29) as well as in mCRPC patients in the 
post-chemotherapy setting (15.8 vs 11.2 months for placebo, p < 0.0001) (30). In the 
post-chemotherapy setting, Abiraterone was also found to have a significant effect on 
radiographic PFS (rPFS) (5.6 vs 3.6 months for placebo, p < 0.0001) (30).  
Enzalutamide is a non-steroidal anti-androgen that inhibits androgen receptor 
signalling pathways. It competitively binds to androgen receptors, inhibits androgen 
receptor translocation to the cell nucleus, and inhibits binding of androgen receptors 
to DNA (31). In chemotherapy naïve PCa patients, Enzalutamide demonstrated a 
significant effect on rPFS and OS. At 12 months, the rate of rPFS was 65% vs 14% 
for placebo and there was a 29% decrease in the risk of death compared with placebo 
(p < 0.001) (31). Enzalutamide has also shown significantly improved OS in the 
post-chemotherapy setting (18.4 vs 13.6 months for placebo, p < 0.001) (32).  
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1.4.3. CHEMOTHERAPY 
Docetaxel is an anti-mitotic chemotherapy agent that is used as first-line 
chemotherapy in PCa patients. Compared with Mitoxantrone, which is another 
chemotherapeutic agent that relieves pain and improves quality of life but does not 
improve OS, Docetaxel was found to improve OS (18.9 months vs 16.5 months, 
p = 0.009 and 17.5 vs 15.6 months, p = 0.002) (33, 34) as well as rPFS (16.5 vs 8.2 
months, p < 0.001) (35). A recent meta-analysis demonstrated that Docetaxel in 
combination with primary ADT for patients with androgen-dependent metastatic and 
non-metastatic PCa is associated with improved survival (p = 0.003) (36).  
Cabazitaxel is a microtubule inhibitor, which is used as a second-line chemotherapy 
option for patients who have previously received Docetaxel. Compared with 
Mitoxantrone, Cabazitaxel showed improved OS and PFS in the post-Docetaxel 
setting with a 30% decrease in the risk of death (37). 
1.4.4. RADIUM-223 
Radium-223 is an alpha-emitting radiopharmaceutical that is used to treat bone 
metastases in PCa. It is absorbed by bone, especially in bone metastases that exhibit 
increased bone turnover. When it has been absorbed, Radium-223 emits highly potent, 
short-range alpha particles and kills cancer cells. It is highly effective for pain relief 
in patients with painful bone metastases and CRPC (38, 39). Furthermore, 
Radium-223 has demonstrated improved OS compared with placebo, 14.9 vs 11.3 
months for placebo (p < 0.001) (40). This PhD study did not involve any patients 
receiving Radium-223.  
 BONE IMAGING IN NUCLEAR MEDICINE 
Reliable detection of bone metastases in PCa is an essential component of patient 
management. Several imaging modalities can be used for this purpose, including 
nuclear medicine and radiological imaging modalities. The most widely used and 
recommended modality for the detection and monitoring of bone metastases in PCa is 
BS (5-7). A brief introduction of nuclear medicine modalities for bone metastases 
imaging in PCa is provided below. Radiological imaging modalities are omitted as 
they are beyond the scope of this PhD thesis.  
1.5.1. PLANAR WHOLE-BODY BONE SCAN 
Bone scintigraphy is a highly sensitive imaging modality that visualises the 
distribution of active bone formation within the skeleton by use of a radioactive tracer, 
99mTc-labelled diphosphonates. It is not a highly specific modality as it not only 
visualises cancerous bone metastases but also benign conditions including 
degenerative and inflammatory bone disease, fractures, and infections (41, 42).  
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1.5.2. SPECT/CT 
Single photon emission computed tomography (SPECT) is a technical enhancement 
of the planar BS in which tomographic image acquisition allows for three-dimensional 
visualisation of tracer uptake. Most often, SPECT is combined with computed 
tomography (CT), thus allowing the opportunity to correlate SPECT findings with 
anatomical image data. Computed tomography is mainly used for attenuation 
correction and anatomical co-localisation (41, 42). Imaging with SPECT/CT is most 
often performed as an add-on to BS and is thus acquired immediately after the BS 
with no additional radiation exposure beyond the CT, which is most often  a low-dose 
CT. 
1.5.3. PET/CT 
18F-sodium fluoride (NaF), which was initially introduced in the 1960s, is a 
bone-specific tracer that, like 99mTc-diphosphonates, visualises sites of increased bone 
turnover. Nevertheless, because of the immense technical requirement for using this 
tracer, the widespread availability of 99mTc-generators, and the low costs associated 
with BS imaging, BS was preferred (43-46). As a consequence of the increasing 
availability of positron emission tomography (PET)/CT scanners, interest in the 
clinical use of NaF for skeletal imaging has spiked in the past decades (47, 48). The 
uptake of NaF is higher compared to 99mTc-diphosphonates. Furthermore, it has a 
faster blood clearance and higher target-to-background ratio. Together with the 
improved spatial resolution of PET scanners, image quality is improved compared 
with BS imaging (43-46). Like with SPECT/CT, CT is often performed 
simultaneously with PET, allowing for attenuation correction and anatomical 
co-localisation. 
Several other PET tracers are currently being used and investigated for the detection 
of bone metastases in PCa. Unlike NaF, these tracers primarily target malignant 
cancer cells. 18F-labelled fluorodeoxyglucose is the most commonly applied 
radiopharmaceutical across many other cancer types . Bone metastases from PCa are 
mostly sclerotic and therefore have lower metabolic activity compared with lytic 
lesions. Thus, these lesions are not particularly avid for 18F-labelled 
fluorodeoxyglucose, and the sensitivity when using this tracer for detection of bone 
metastases in PCa is lower than that of BS (49-51). 18F-acetate, 18F-choline, and 
11C-choline likewise target tumour cells, and have shown promising results with high 
sensitivity and specificity for the detection of bone metastases. However, these 
modalities have not currently been adopted for routine use (52, 53). In addition, 
68Ga-labelled prostate specific membrane antigen is currently under investigation for 
bone imaging in PCa and is showing promising results (54, 55). These tracers are, 
however, not within the scope of this PhD study and will not be discussed further.  
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1.5.4. COMPARISON OF BS, SPECT/CT AND NAF PET/CT 
The diagnostic performance of BS versus SPECT and NaF PET (with or without CT) 
has been investigated in diagnostic test accuracy (DTA) studies on multiple occasions 
during the past decade. Table 2 shows the results of studies involving at least two of 
the imaging modalities of interest in this PhD study, i.e., BS, SPECT/CT and 
NaF PET/CT. The reference standards used in these studies are presented as well. 
Previous studies have included highly heterogeneous and mixed study populations, 
and the studies have had some methodological issues, but this will be addressed more 
thoroughly later. 
The sensitivity of BS in previous studies has varied from as low as 57% to as high as 
97% (50, 51, 56-59). For studies in which the reference standard was primarily based 
on other imaging, e.g., full-diagnostic CT or MRI, the sensitivity of BS was lowest 
(56, 59), while studies that used a combination of imaging, clinical follow-up, etc., 
found a higher sensitivity of BS (50, 51, 57, 58). The specificity of BS has been even 
more wide-ranging with reported values from 57-80% (50, 51, 56-59). 
Independent of whether SPECT was used alone or in combination with CT, the 
sensitivity of SPECT ranged from 78-96% (56-58). When it came to the specificity of 
SPECT, the addition of a CT had a major impact on the results. The specificity for 
SPECT alone was in the range of 56-64% (57, 58), while the specificity for 
SPECT/CT ranged from 67-96% (56-58).  The improved specificity is probably due 
to the attenuation correction and anatomical co-localisation gained from CT. 
The sensitivity of NaF PET/CT studies has, in most studies, been 100% (50, 51, 56, 
57, 59, 60). In a few studies in which NaF PET/CT was compared with 
18F-choline PET/CT, the sensitivity of NaF PET/CT was 81% (61, 62). The specificity 
of NaF PET/CT has shown greater variation with reported specificities ranging from 
71-100% (50, 51, 56, 57, 59-62). 
When comparing the results for BS, SPECT/CT and NaF PET/CT, the sensitivity of 
NaF PET/CT was higher than those of SPECT/CT and BS across all studies (50, 51, 
56-59). The specificity of NaF PET/CT was outperformed by that of SPECT/CT in 
the study by Jambor et al. (57). The sensitivity of SPECT/CT was higher than or equal 
to BS in all studies, and the specificity was higher (56-58). In summary, the diagnostic 
performance of these three imaging modalities can be ranked with NaF PET/CT 
demonstrating the best diagnostic performance, followed by SPECT/CT and BS. 
However, even though studies continue to demonstrate an apparent advantage of 
NaF PET/CT and SPECT/CT over BS, current guidelines have refrained from 
including SPECT/CT, NaF PET/CT, or other PET tracers as standard imaging options 
for the detection of bone metastases in PCa (5-7). The rationale behind this is probably 
that there is a lack of clear-cut evidence and varying degrees of methodological issues 
with these studies. 
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1.5.5. CHALLENGES IN DIAGNOSTIC TEST ACCURACY STUDIES 
Previous DTA studies within bone imaging in PCa have included highly 
heterogeneous and limited study populations with various cancer types and have 
included both newly diagnosed patients and those evaluated for re-staging purposes. 
In addition, the reference standard has often relied on clinical follow-up, which has 
not been clearly defined, and sometimes the reference standard was predominantly 
based on consensus evaluation of the index test, thus resulting in an artificially boosted 
performance due to circular reasoning (50, 51, 56-62). The methodological issues 
were summarised in a review by Wondergem et al., who also determined that the level 
of evidence in these DTA studies was quite low, Oxford Centre for Evidence-Based 
Medicine level 3b  (53, 63).  
The persistent presence of methodological issues within DTA studies has long been 
known, and some common issues include poorly described study populations and 
sampling procedures, and verification bias (64-67). A major issue is that for most 
diseases and conditions, it is practically impossible to obtain a single perfect “gold” 
reference standard, and in previous studies, the reference standard has varied and 
different solutions have been used to account for imperfect or missing values of the 
reference standard (68). Within bone imaging, the theoretical “gold” reference 
standard would be biopsies and histological verification of bone metastases, but this 
is neither practical nor ethically reasonable; in DTA studies with PCa and bone 
metastases consensus reviews or expert panels are commonly used (Table 2) (51, 57, 
58). In recent years, the use of expert panels has increased, i.e., a consensus reading 
between a group of experts who determine the final diagnosis on the basis of all 
available relevant data for each patient (69). While not perfect, this might be one of 
the more ideal approaches, as it resembles clinical practice. Bertens et al. (69) 
investigated the use and reporting of expert panels in DTA studies and concluded that 
expert panels can be used in the absence of a single “gold standard”, and they 
encouraged the development of formal methodology guidelines. 
 
  
10 
 
T
ab
le
 2
 C
om
pa
ris
on
 o
f t
he
 d
ia
gn
os
tic
 p
er
fo
rm
an
ce
 o
f b
on
e 
im
ag
in
g 
m
od
al
iti
es
in
 n
uc
le
ar
 m
ed
ic
in
e 
R
ef
er
en
ce
 st
an
da
rd
 
C
T 
fr
om
 N
aF
 
PE
T/
C
T 
Fu
ll 
di
ag
no
st
ic
 C
T 
or
 o
r M
R
I 
Ex
pe
rt 
pa
ne
l r
ev
ie
w
 
of
 h
is
to
lo
gi
ca
l 
co
nf
irm
at
io
n,
 
cl
in
ic
al
 fo
llo
w
-u
p,
 
an
d 
ot
he
r i
m
ag
in
g 
M
R
I, 
th
in
 sl
ic
e 
co
nt
ra
st
-e
nh
an
ce
d 
C
T,
 o
r s
ke
le
ta
l 
ra
di
og
ra
ph
 fi
nd
in
gs
 
A
cc
ur
ac
y 
- - - - 78
 
79
 
90
 
94
 
78
 
90
 
N
PV
 
55
 
74
 
10
0 
10
0 
89
 
10
0 - - 88
 
10
0 
PP
V
 
59
 
72
 
74
 
10
0 
54
 
75
 
- - 76
 
87
 
Sp
ec
ifi
ci
ty
 
57
 
67
 
62
 
10
0 
82
 
90
 
80
 
80
 
41
 
71
 
Se
ns
iti
vi
ty
 
57
 
78
 
10
0 
10
0 
67
 
10
0 
88
 
10
0 
97
 
10
0 
In
de
x 
te
st
s 
B
S 
SP
EC
T/
C
T 
N
aF
 P
ET
 
N
aF
 P
ET
/C
T 
B
S 
+S
PE
C
T 
N
aF
 P
ET
/C
T 
B
S 
N
aF
 P
ET
/C
T 
B
S 
+S
PE
C
T 
N
aF
 P
ET
/C
T 
n 
(N
D
/R
S)
 
44
 
(2
5/
19
) 
10
 
(1
0/
0)
 
18
 
(0
/1
8)
 
49
 
(2
5/
24
) 
St
ud
y 
E
ve
n-
Sa
pi
r 
20
06
 (5
6)
 
W
ith
of
s 
20
11
 (5
9)
 
 
Ia
ga
ru
 
20
12
 (5
1)
 
D
am
le
 
20
12
 (5
0)
 
DIAGNOSIS AND MONITORING OF BONE METASTASES IN PROSTATE CANCER 
11 
 
T
ab
le
 2
 c
on
tin
ue
d 
C
om
pa
ris
on
 o
f t
he
 d
ia
gn
os
tic
 p
er
fo
rm
an
ce
 o
f b
on
e 
im
ag
in
g 
m
od
al
iti
es
in
 n
uc
le
ar
 m
ed
ic
in
e R
ef
er
en
ce
 st
an
da
rd
 
Ex
pe
rt 
pa
ne
l r
ev
ie
w
 
of
 c
lin
ic
al
 fo
llo
w
-u
p,
 
in
cl
ud
in
g;
 c
lin
ic
al
 
ex
am
in
at
io
n,
 
m
ed
ic
al
 re
po
rts
, 
im
ag
in
g,
 a
nd
 tu
m
ou
r 
m
ar
ke
rs
 
Ex
pe
rt 
pa
ne
l r
ev
ie
w
 
of
  i
nd
ex
 te
st
 re
su
lts
, 
fo
llo
w
-u
p 
da
ta
 (6
-3
2 
m
on
th
s)
 o
f c
lin
ic
al
, 
im
ag
in
g,
 a
nd
 
la
bo
ra
to
ry
 d
at
a 
V
al
ue
s o
f s
en
si
tiv
ity
, s
pe
ci
fic
ity
, P
PV
, a
nd
 N
PV
 a
re
 p
re
se
nt
ed
 w
ith
 e
qu
iv
oc
al
 re
su
lts
 re
ga
rd
ed
 a
s m
al
ig
na
nt
. 
N
D
, n
ew
ly
 d
ia
gn
os
ed
; R
S,
 r
e-
st
ag
in
g;
 P
PV
, p
os
iti
ve
 p
re
di
ct
iv
e 
va
lu
e;
 N
PV
, n
eg
at
iv
e 
pr
ed
ic
tiv
e 
va
lu
e;
 B
S,
 p
la
na
r 
w
ho
le
-b
od
y 
bo
ne
 s
ci
nt
ig
ra
ph
y;
 S
PE
C
T,
 s
in
gl
e-
ph
ot
on
 e
m
is
si
on
 t
om
og
ra
ph
y;
 C
T,
 c
om
pu
te
d 
to
m
og
ra
ph
y;
 N
aF
, 1
8 F
-s
od
iu
m
 f
lu
or
id
e;
 P
ET
, 
po
si
tro
n 
em
is
si
on
 to
m
og
ra
ph
y;
 M
R
I, 
m
ag
ne
tic
 re
so
na
nc
e 
im
ag
in
g.
 
A
cc
ur
ac
y 
- - - 67
 
69
 
90
 
89
 
N
PV
 
98
 
98
 
99
 
- - - - 
PP
V
 
61
 
52
 
87
 
- - - - 
Sp
ec
ifi
ci
ty
 
75
 
64
 
94
 
59
 
56
 
88
 
82
 
Se
ns
iti
vi
ty
 
96
 
96
 
96
 
85
 
95
 
95
 
10
0 
In
de
x 
te
st
s 
B
S 
SP
EC
T 
SP
EC
T/
C
T 
 B
S 
SP
EC
T 
SP
EC
T/
C
T 
N
aF
 P
ET
/C
T 
n 
(N
D
/R
S)
 
97
 (-
/-)
 
27
 
(0
/2
7)
 
St
ud
y 
Pa
lm
ed
o 
20
13
 (5
8)
 
Ja
m
bo
r 
20
16
 (5
7)
 
12 
 
Standards for Reporting of Diagnostic Accuracy  
In an attempt to improve the quality of reporting of all aspects of DTA studies, 
Bossuyt and colleagues (70) published the Standards for Reporting of Diagnostic 
Accuracy (STARD). The original STARD checklist contained 25 specific items to be 
included in the abstract, title, methods, results, and discussion that are needed for 
complete and accurate reporting in DTA studies. In 2015, Korevaar et al. (66) 
investigated the reporting of the items included in the STARD checklist and compared 
this to articles published before STARD and one and 10 years after STARD was first 
published. They found that reporting in DTA studies has improved since the initiation 
of STARD. However, there are still some shortcomings, especially regarding patient 
selection, details on the readers of index tests, and variations in the accuracy of the 
index test between subgroups of patients, centres, and/or readers. The STARD 
checklist was updated in 2015 with additional essential items to improve completeness 
and transparency in DTA studies (71). In summary, some attempts have been made to 
improve the design and reporting of DTA studies. While some progress has been seen 
in recent years, there is still room for improvement.  
 TREATMENT RESPONSE ASSESSMENT 
1.6.1. RESPONSE ASSESSMENT METHODS 
Disease monitoring is essential for optimal patient management, especially with the 
dramatic increase in the cost of cancer therapies that has occurred over the past years 
(72-74).  Response assessment is standard when evaluating the efficacy of new 
therapeutic agents in cancer imaging. In PCa, it remains a challenge to determine 
response to therapy, as most patients with metastatic PCa have disease limited to bone, 
and it is well-known that assessment of treatment response in bone metastases is 
difficult (75). 
RECIST and PERCIST 
The most commonly used set of response criteria in cancer imaging is the Response 
Evaluation Criteria in Solid Tumours (RECIST) (76), which classifies sclerotic bone 
lesions as non-measurable. These criteria are therefore of little use when determining 
response of bone metastases and are hence of limited use in PCa (77). Current 
guidelines recommend BS for monitoring bone metastases (6, 7, 11). The RECIST 
criteria were adapted for use in PET in 2009 as the Positron Emission Tomography 
Response Criteria in Solid Tumours criteria (PERCIST) (78). As with RECIST, 
PERCIST has not gained footing within PCa as a large proportion of PCa patients 
remain non-evaluable by PERCIST (79). These criteria are, due to their limited 
applicability in PCa, beyond the scope of this PhD thesis and will not be described 
further. 
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MD Anderson criteria 
Because of the lack of criteria for assessment of tumour response in bone, Hamaoka 
et al. (80) proposed a set of visual assessment criteria for evaluation of bone metastatic 
response, known as the MD Anderson criteria. These criteria included similar 
response categories as those used by RECIST, i.e., complete response, partial 
response, stable disease or progressive disease, but instead of quantifying response 
they focused on acknowledging the presence of a response. Besides BS, the 
MD Anderson criteria included plain radiographs, CT and MRI, but these are beyond 
the scope of this PhD thesis. It has been shown that the MD Anderson criteria are able 
to distinguish responders (complete and partial response) from non-responders (stable 
and progressive disease) with regard to PFS in bone-only metastatic breast cancer 
patients receiving systemic treatment (23.3 vs 5.5 months, respectively, p = 0.025) 
(81). Improved OS was likewise demonstrated for responders vs non-responders (61.9 
vs 34.4 months, not significant p=0.13) (81). No studies have investigated this 
relationship in PCa patients. 
Prostate Cancer Working Group Criteria 
It has been a great challenge to determine the efficacy of new therapeutic agents in 
PCa studies without excluding patients with non-measurable disease. Therefore, the 
Prostate-Specific Antigen Working Group was established in an attempt to develop 
consensus criteria for response assessment in PCa studies (82); they were revised in 
2008 with the Prostate Cancer Working Group (PCWG) 2 criteria (83), and in 2016 
the PCWG-3 criteria were published (24). These response evaluation criteria 
addressed symptoms, biochemical response, response of measurable disease, and 
response of non-measurable bone lesions. Since their introduction, the PCWG criteria 
have been widely adopted in clinical trials for the assessment of treatment response in 
bone (30-32, 84, 85).  
The focus of the PCWG criteria is to rule out or identify the presence of progression 
on BS. Unlike RECIST and the MD Anderson criteria, the PCWG criteria do not 
distinguish between stable disease and improvement (partial or complete response) 
and include only two response categories: 1) progressive disease (PD) and 2) 
non-progressive disease (non-PD).  
Progressive disease according to the PCWG criteria was associated with OS in a large 
population of men with CRPC, where PD at three months was associated with a 
median OS of 9.2 months vs 17.8 months in patients showing non-PD (p < 0.0001) 
(86). At six months, median OS was 10.1 months for PD vs 19.3 months non-PD 
(p < 0.0001) (86).  
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1.6.2. TREATMENT RESPONSE ASSESSMENT IN BONE BY BS AND 
NAF PET/CT 
Only very few studies have directly investigated the use of BS and other imaging 
modalities for bone response in PCa.  
Bone scan response assessment 
Sonpavde and colleagues (87) collected data from two large prospective clinical trials 
and showed that radiographic progression according to the PCWG-2 criteria was 
associated with poorer OS in patients taken off study due to radiographic progression 
vs patients who were taken off study for other reasons.  
In a large clinical trial comparing abiraterone acetate vs placebo rPFS, according to 
the PCWG-2 criteria, was positively correlated with OS (Spearman correlation 
coefficient (R2) = 0.72, 95% CI: 0.65-0.77) (88). The positive correlation was evident 
in both the treatment group and the placebo group. Furthermore, in the entire group 
of patients, OS was shorter for those who met the PCWG-2 criteria for confirmed PD 
on a subsequent scan compared with those who did not have confirmed PD (88).  
In patients who had previously failed Docetaxel chemotherapy and were assigned to 
treatment with Radium-223, response on BS was mixed, showing the appearance of 
new lesions simultaneously with decreased tracer uptake in bone metastases that 
demonstrated a high pre-treatment uptake (89).  
In recent years, studies have found a correlation between OS and bone response, 
defined as changes in the Bone Scan Index, a quantitative imaging biomarker 
developed for assessment of bone tumour load on BS (90-94). Kaboteh et al. (93) 
compared the correlation between OS and bone response by changes in the Bone Scan 
Index and response according to the PCWG-2 criteria. Although it was a small and 
retrospective study, they showed that changes in the Bone Scan Index correlated with 
OS, while progression by the PCWG-2 criteria did not.  
In summary, the results of the above studies indicate that progression on BS, either 
according to the PCWG criteria or as changes in Bone Scan index, can be correlated 
with OS and BS is therefore useful in determining response to therapy. 
Observer agreement for assessment of BS 
An important aspect of treatment monitoring is the consistency of response 
classification among observers. When analysed by Cohen’s kappa, inter-observer 
agreement for the diagnosis of bone metastases is reportedly moderate to almost 
perfect depending on the number of categories used for classification of the presence 
of bone metastases (95-97). Kaboteh et al. (93) assessed BS according to the PCWG-2 
criteria and found an agreement of 87% (222/255) among three experienced readers 
for evaluation of PD vs non-PD. No kappa values were reported. In 173 PCa patients 
with bone metastases, evaluation of treatment response on BS showed substantial 
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agreement by Cohen’s kappa when using the PCWG-2 criteria (Cohen’s kappa: 0.66) 
and standard clinical assessment (Cohen’s kappa: 0.70) (98). However, knowledge on 
observer agreement for assessment of treatment response on BS and has not been 
investigated at all for NaF PET/CT. A high level of agreement between observers is 
important as decisions to continue or discontinue treatments and investigational 
treatments are often based on the detection of progression on BS. 
NaF PET/CT response assessment 
A few minor studies have investigated changes on NaF PET/CT.  
Cook et al. (99) showed that changes on NaF PET/CT, as measured by changes in 
standardised uptake values (SUV), closely followed changes in PSA in five patients 
after receiving two doses (six weeks apart) of Radium-223.  
In a mixed population of bone metastases-positive and -negative PCa patients who 
were undergoing a wide range of treatments, Apolo and colleagues investigated 
changes on NaF PET/CT at 6 and 12 months and correlation with clinical assessment 
of bone response and PSA (100). Clinical assessment of bone response was 
categorised as regression (regression of existing lesions), stable disease (no new 
lesions) or progression (new lesions). Changes in SUV correlated with clinical 
assessment of bone response at 6 and 12 months when analysed by the Kruskal-Wallis 
rank test (p = 0.0147 and p = 0.0053, repectively). Likewise, there was a correlation 
between change in PSA and maximal percent change in SUV at 6 and 12 months (R2 
= 0.39, p = 0.014 and R2 = 0.58, p = 0.0005, respectively) (100).   
Kairemo et al. (101) investigated changes on NaF PET/CT in 10 mCRPC patients 
receiving Radium-223. They summed the two highest SUV from two skeletal regions 
and found that after six cycles of Radium-223 all patients responded on NaF PET/CT 
with ≥ 6% change in SUV compared to baseline. This was accompanied by changes 
in PSA in some but not all patients. 
A survey of the National Oncologic PET Registry in America showed that patient 
management was changed in up to 53% of PCa patients following a NaF PET/CT 
(16% when adjusted for patients who already had a pre-treatment plan involving 
imaging). However, this study did not investigate whether the change in management 
led to improved patient outcome (47). 
Thus, previous studies on response assessment by NAF PET/CT are scarce, has 
included small study populations, have not compared the results with BS, and 
furthermore, no studies have investigated response on NaF PET/CT in relation to 
patient outcome. 
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 RATIONALE FOR PHD STUDIES 
Although there is a growing body of evidence showing an apparent superiority of NaF 
PET/CT and SPECT/CT over BS, the methodological issues in previous DTA studies, 
as outlined in section 1.5.5., discouraged clinical guidelines from including these 
newer modalities as standard for the diagnosis of bone metastases in PCa. Therefore, 
properly designed studies are needed to establish the improved diagnostic 
performance of these modalities. 
Monitoring of treatment responses in bone is essential for patient management in PCa, 
both in clinical trials and in clinical practice. Clinical guidelines recommend using BS 
for monitoring of bone metastases in PCa and the PCWG advocate the use of BS for 
determination of bone progression in clinical trials. It is essential for patient 
management that there is a high level of agreement for response classification between 
readers. Different methods for response classification have been presented; however, 
observer agreement has not been adequately investigated. Delineation of such 
agreement is necessary to establish the best method for future use in treatment 
response monitoring in bone.  
Finally, the use of NaF PET/CT in PCa is increasing both for diagnostic purposes as 
well as for treatment response monitoring. No studies have investigated the use of 
NaF PET/CT for treatment response assessment in comparison with conventional BS, 
for which response classification is correlated with OS. Therefore, studies are needed 
to investigate the concordance between BS and NaF PET/CT for treatment response 
assessment and how they might differ.
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CHAPTER 2. AIMS 
The overall aim of this PhD thesis was to evaluate BS, SPECT/CT and NaF PET/CT 
for diagnosis and monitoring of bone metastases in PCa. This was done in three 
sub-studies, for which the specific aims are listed below. 
Study I (Papers 1 & 2) 
To compare the diagnostic performances of BS, SPECT/CT and NaF PET/CT in 
newly diagnosed high-risk PCa patients in a fully STARD-compliant DTA study 
(102).  
Study II (Paper 3) 
To evaluate observer agreement in the assessment of treatment responses in bone on 
BS in PCa patients undergoing different anti-cancer treatments at varying stages of 
PCa, using three different methods for treatment response evaluation (103). 
Study III (Paper 4) 
To prospectively explore the concordance between BS and NaF PET/CT when 
evaluating bone metastases response in PCa patients receiving various anti-cancer 
treatments and to explore the relationships between imaging, clinical, and biochemical 
responses.  
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CHAPTER 3. MATERIALS AND 
METHODS 
 STUDY POPULATION  
Study I 
From February 2014 to December 2015, consecutive patients with newly diagnosed 
high-risk PCa from the Departments of Urology at Aalborg University Hospital, 
Regional Hospital West Jutland Holstebro, and Regional Hospital Viborg were invited 
to participate in this study. Eligibility criteria consisted of the following: 
1) biopsy-proven PCa; 2) PSA blood levels ≥ 50 ng/mL; 3) eligible for ADT; 4) no 
other cancer within five years; 5) ability to comply with study procedures; and 6) have 
not received any investigational drugs.  
The Regional Research Ethics committee (N-20130068) and the Danish Data 
Protection Agency approved the study. Written informed consent was obtained from 
52 patients. Of these, 10 patients either withdrew consent or were excluded for 
incompatibility reasons. Furthermore, three patients died before completion of the 
study, resulting in 39 patients remaining. Two of these were excluded from the final 
analysis because a final diagnosis could not be determined. 
Study II  
In this retrospective study, all patients who, during the period from January 2009 to 
November 2014, had undergone two or more bone scans within one year at the 
Department of Nuclear Medicine, Aalborg University Hospital, were identified from 
the hospital records (103). Patients were then selected according to the following 
criteria: 1) patients were treated with either ADT, NGH, or chemotherapy; and 2) 
patients had two BS performed within the same treatment, a baseline BS and a 
follow-up BS. The baseline BS was performed within three months before initiation 
of therapy or a maximum 14 days within treatment. The follow-up BS was performed 
12-52 weeks within treatment for patients receiving ADT and 12-30 weeks within 
treatment for patients receiving NGH or chemotherapy. Patients treated successively 
with different treatments and with more than one BS pair fulfilling the above criteria 
were allowed to enter the study twice (103). 
A total of 105 patients were identified from the hospital records. Of these, 55 patients 
with 63 evaluable BS pairs fulfilled the above criteria and were included in the final 
analyses (103).  
Study III 
Patients from Study I who had completed all study-related procedures were included 
in Study III along with consecutive patients with confirmed bone metastases (by 
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clinical evaluation) scheduled to receive either primary ADT, NGH, or chemotherapy. 
The latter patients were included in a separate protocol approved by the Regional 
Research Ethics committee (N-20140057) and the Danish Data Protection Agency. 
Eligibility criteria for this protocol were as follows: 1) histologically confirmed PCa; 
2) bone metastases on BS at inclusion; 3) clinical life expectancy > six months; 4) no 
other cancer within five years; and 5) ability to comply with study procedures.  
A total of 64 patients were included in the final analysis in this study, 23 of which 
originated from Study I.  
 METHODS 
3.2.1. SCANS 
All scans were performed according to current institutional guidelines, which are 
consistent with European and International guidelines (41-43, 46). Scans were 
performed at Aalborg University Hospital or at Regional Hospital West Jutland 
Herning. 
3.2.1.1 Planar Whole-Body Bone Scan 
Aalborg 
Bone scans were performed on Symbia dual-head gamma cameras with multi-
purpose, low-energy, high-resolution collimators (Symbia T16, Siemens Medical 
Solutions, Erlangen, Germany). Data acquisition was performed two to three hours 
after intravenous administration of 750-1000 MBq 99mTc-labelled diphosphonate, 
with a scan speed of 24 cm/min. The use of an alpha blending technique allowed for 
an apparent increase in counts by a factor of two, thus accounting for the faster 
acquisition time in Aalborg. 
Herning 
Bone scans were performed on Symbia dual-head gamma cameras with multi-
purpose, low-energy, high-resolution collimators (Symbia T2 and T16, Siemens 
Medical Solutions, Erlangen, Germany). Data acquisition was performed two to three 
hours after intravenous administration of 10 MBq/kg 99mTc-labelled diphosphonate, 
with a scan speed of 10 cm/min. 
3.2.1.2 SPECT/CT 
Aalborg 
A three-bed SPECT/CT scan, from vertex to mid-thigh, was performed immediately 
following the planar imaging using the following parameters: matrix 128 x 128, zoom 
factor 1, 20 s per view, 32 views, and rotation of the detectors by 180 degrees in a 
non-circular orbit using step-and-shoot mode. A low-dose CT without intravenous 
contrast was acquired and used for attenuation correction and anatomical co-
registration: 30 mA, 130 kV, slice thickness 3 mm. 
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Herning 
A three-bed SPECT/CT scan, from vertex to mid-thigh, was performed immediately 
following the planar imaging using the following parameters: matrix 128 x 128, zoom 
factor 1, 10 s per view, 64 views, and rotation of the detectors by 180 degrees in a 
non-circular orbit in a continuous mode. The low-dose CT had the following 
parameters: reference mA 100 (CARE dose), 130 kV, and a slice thickness of 5 mm. 
3.2.1.3 NaF PET/CT 
Aalborg 
Patients were scanned on a dedicated VCT discovery True 64 PET/CT, 
(GE Healthcare). Scans were performed after intravenous administration of 200 MBq 
NaF in 3D mode from vertex to mid-thigh, encompassing 7-9 bed position (150 s per 
bed position). The images were reconstructed by iterative construction, using 
low-dose CT images for attenuation correction and anatomical co-localisation. The 
CT parameters were 70-200 mA smart mA, 120 kV. The slice thickness was 0.625 
mm. 
Herning 
Patients were scanned on a dedicated Biograph mCT 64, 4R PET/CT (Siemens 
Medical Solutions). All scans were performed 30 minutes after intravenous 
administration of approximately 200 MBq NaF in 3D mode from vertex to mid-thigh, 
encompassing 7-9 bed positions (120-180 s per bed position according to body mass 
index). Images were reconstructed as in Aalborg, using low-dose CT images for 
attenuation correction and anatomical co-localisation. The CT parameters were 
30 mAs, 120 kV. The slice thickness was 0.625 mm.  
3.2.2. IMAGING SCHEDULE 
Study I 
Patients were scanned at baseline and after 26 weeks of therapy. Patients were 
routinely referred for BS for staging purposes. As an add-on, the three-bed SPECT/CT 
was performed immediately after the BS. NaF PET/CT was then performed. All scans 
had to be performed before or a maximum of 14 days within treatment. After 26±4 
weeks, all three scans were repeated, and these data were used to assist in the 
determination of a final diagnosis (102). Figure 2 shows the scan times and the number 
of patients scanned at each time-point. 
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Figure 2 An overview of scan times in Study I, and the number of scans available for evaluation at each 
time-point. BS, bone scan; SPECT/CT, single-photon emission computed tomography / computed 
tomography; NaF PET/CT, 18F-sodium fluoride positron emission tomography /CT. 
3.2.2.1 Study II 
See Study Population, section 3.1, Study II (103).  
Study III  
Before initiation of either ADT, NGH, or chemotherapy, patients were routinely 
referred for BS for assessment of bone metastases status. Additionally, a NaF PET/CT 
scan was performed no later than 14 days within treatment. These constituted the 
baseline scans. Including the baseline scans, imaging with BS and NaF PET/CT was 
performed 2-4 times within a 26-week time period for patients receiving ADT or NGH 
and 2-3 times within a 20-week time period for patients receiving chemotherapy. 
Figure 3 shows the scan times and the number of patients scanned at each time-point 
by treatment.  
 
 
Figure 3 An overview of scan times for Study III, and the number of evaluable scans at each time point 
according to treatment. This includes patients who had both a bone scan and a 18F-sodium fluoride 
positron emission tomography/computed tomography at each time point. 
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3.2.3. IMAGE ANALYSIS 
For all three studies, specific forms and guides for completion of these were designed. 
These are presented in Appendices A-C. 
Study I 
Expert readings 
Two nuclear medicine specialists with more than 10 years of experience with BS 
evaluated all BS images. Likewise, two nuclear medicine specialists with 5 and 10 
years of experience with NaF PET/CT evaluated all NaF PET/CT images. Readers 
were blinded to any clinical and biochemical information regarding the patients, 
except for the diagnosis of high-risk PCa. Readers were first asked to rate the images 
on a three-point scale of benign (M0), equivocal (Me), or malignant (M1) and 
subsequently on a dichotomous scale of M0 or M1. The readers were then asked to 
indicate if the patient had more than 10 suspicious bone lesions or a scan compatible 
with superscan. Finally, the readers were asked to draw lesions on a schematic 
drawing of the skeleton if the patient had 10 or fewer suspicious bone lesions. The 
readers used the form included in Appendix A-1 and were guided by A-2. In cases of 
disagreement, the readers performed a consensus reading.  
Reference standard 
To determine the final diagnosis, a multidisciplinary committee consisting of 
experienced specialists, a urologist, a radiologist and a nuclear medicine physician 
reviewed all relevant and available information about each patient. The reference 
standard was thus a compilation of the following:  
1) Results of the expert readings  
2) All available baseline and follow-up imaging 
3) All available biochemical information about the patient 
4) A standard questionnaire filled out routinely with each BS including 
information about any bone-related disease or trauma, joint replacements, 
and any unexplained bone pain.  
5) If necessary, any existing routine imaging was also made available if a final 
diagnosis could not be determined based on points 1-4. 
The multidisciplinary committee used the form included in Appendix A-3.  
Study II 
Five experienced nuclear medicine physicians participated in the evaluation of images 
in Study II (103). Two readers evaluated each baseline and follow-up image 
individually (Appendix B-1). Images were evaluated for the presence of bone 
metastases (M0/M1) and the number of suspicious lesions within five skeletal regions 
(skull, thorax incl. sternum, columna, pelvis, and extremities incl. scapula). Readers 
were asked to count up to 20 lesions within each region (103), and these counts were 
subsequently reclassified according to the extent of disease classification by 
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Soloway et al. (104). Each pair of baseline and follow-up images was then evaluated 
side-by-side for response using three different methods for response evaluation; 
readers classified patients according to specific response categories as shown in 
Table 3 and Appendix B-2, B-3, B-4 (103). 
The image pairs were evaluated three times by three different methods. Therefore, to 
account for the bias that the readers could remember an image pair, the image pairs 
were evaluated by two different readers for each response evaluation method. For 
instance, for Patient 1, readers 1 and 2 evaluated the images by Standard Clinical 
Assessment, readers 3 and 4 evaluated them by MD Anderson criteria, and readers 5 
and 1 evaluated them by the PCWG-2 criteria (103).  
 
Table 3 Response assessment methods and categories 
Response criteria Response categories 
Standard clinical 
assessment 
Regressive disease 
  -Regression of lesions/disappearance of hot spots 
Stable disease 
  -No change 
Progressive disease 
  -Progression of lesions/new lesions 
MD Anderson (80) Complete response 
  -Disappearance of hot spots or tumour signal 
Partial response 
  -Regression of lesions 
Stable disease 
  -No new lesions 
Progressive disease 
  -New lesions or increased activity 
Prostate Cancer 
Working Group 2 (83) 
Non-progressive disease 
  -No or maximum one new lesion 
Progressive disease 
  -Two or more new lesions, confirmed on 
subsequent scan (if one existed) 
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Study III 
The same nuclear medicine specialists who performed the expert readings in Study I 
evaluated all BS and NaF PET/CT images in Study III. Readers received careful 
instructions on how to evaluate images (Appendix C-1). 
As in Study II, readers first determined the presence of bone metastases (M0/M1) and 
the number of bone metastases in the following intervals: 0, 1, 2-4, 5-9, 10-20, or >20 
(modified from Soloway et al (104)) (Appendix C-2). The readers were then asked to 
evaluate images for response using modified PCWG-2 criteria (Table 3). The baseline 
scan was evaluated side-by-side with the first follow-up scan (Appendix C-3). In the 
case of PD, the second follow-up scan (if one existed) was used to confirm the 
presence of PD (Appendix C-4). In the case of non-PD, the baseline and the second 
follow-up scan (if one existed) were evaluated side-by-side (Appendix C-5), and then 
the third follow-up scan (if present) was used to confirm any PD. Additionally, readers 
were asked to rate the images according to Standard Clinical Assessment as described 
in Table 3 and Appendix C-1 to C-5.  
3.2.4. BIOCHEMICAL MEASUREMENTS (STUDIES I AND III) 
Prostate specific antigen 
In Study I, blood levels of PSA were measured at baseline and at each subsequent set 
of follow-up scans. The same applied for patients receiving ADT or NGH in Study III. 
For patients receiving chemotherapy in Study III, PSA was measured at several 
varying time points during the study according to clinical practice.  
Changes in PSA were classified according to the PCWG criteria as non-PD or PD. 
Non-progressive disease included PSA response (a decrease in PSA of > 50%) and 
stable disease (decrease in PSA of ≤ 50% or increase < 25%). Progressive disease 
included drifters (initial PSA response followed by progression, with a ≥ 25% increase 
in PSA from nadir) and progressive disease (an increase in PSA of ≥ 25% from nadir).  
Testosterone 
In Study I, testosterone levels were measured at baseline and at each subsequent set 
of follow-up scans. This was done to ensure that levels fell below castration levels 
during treatment, thus confirming that the treatment was effective in performing a 
medical castration, even in cases of progressing PSA levels.  
In Study III, the same as above applied for patients receiving ADT. For patients 
receiving NGH, the testosterone levels were measured to ensure that patients were 
correctly classified as having CRPC. As it had no clinical significance, testosterone 
levels were not measured in patients receiving chemotherapy. 
 
  
26 
 
3.2.5. CLINICAL RESPONSE ASSESSMENT (STUDY III) 
Assessment of clinical response to therapy was performed retrospectively based on 
patient charts. The responsible urologist reviewed charts for all patients receiving 
ADT or NGH and the responsible oncologist reviewed charts for patients receiving 
chemotherapy. Clinical response was based on changes in performance status, pain 
and other cancer-related symptoms. Response was assessed on a three-point scale: 
regression, stable disease, or progressive disease. 
3.2.6. STATISTICS 
Data are presented only on a patient level, and no lesion-based analyses were 
performed for this PhD thesis. Statistical analysis was performed using StataIC 
version 13 (StataCorp LCC, TX, USA) and Microsoft Office Excel 2013.  
Study I 
Sample size was based on recommendations for sample size calculations in DTA 
studies (102, 105). Sensitivity, specificity, and positive and negative predictive values 
were calculated for all three imaging modalities, BS, SPECT/CT, and NaF PET/CT, 
and presented with 95% confidence intervals (CI). The diagnostic performances were 
compared using McNemar’s test.  
Study II 
Agreement between assessments of the presence of bone metastases and for response 
evaluations was calculated using Cohen’s kappa (106).  The terminology by Landis 
and Koch was used to evaluate the extent of agreement according to kappa values, 
where 0.00-0.20: slight; 0.21-0.40: fair; 0.41 – 0.60: moderate; 0.61 – 0.80: 
substantial; and 0.81 – 1.00: almost perfect agreement (107). These are presented with 
95% CIs as well. Bland-Altman plots (108) were constructed to assess the difference 
between readers when counting the number of bone lesions on BS within five skeletal 
regions (103).  
Study III 
The proportions of PD vs non-PD for BS and NaF PET/CT, biochemical and clinical 
response assessments were compared using the McNemar test with p < 0.05 
considered statistically significant. Data are presented with 95% CIs. Agreement 
between BS and NaF PET/CT for response evaluation was evaluated by Cohen’s 
kappa for the total study population. Crude agreement was presented for the individual 
treatment groups.   
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CHAPTER 4. RESULTS 
A brief summary of the main results of each paper is presented below. Detailed 
description of the results are found in the individual papers.  
 PAPER 1 
18F-fluoride positron emission tomography/computed tomography and bone 
scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk 
prostate cancer patients: study protocol for a multicentre, diagnostic test 
accuracy study. 
Randi F. Fonager, Helle D. Zacho, Niels C. Langkilde and Lars J. Petersen 
BMC Cancer (2016) 16:10. DOI 10.1186/s12885-016-2047-1 (102) 
Summary 
Study I was a fully STARD-compliant DTA study. Paper 1 presents the study 
protocol, which includes detailed descriptions of the study design, the study 
population and rationale for selection of patients. Furthermore, it includes descriptions 
of imaging procedures and a detailed plan for image analysis.
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 PAPER 2 
Diagnostic test accuracy study of 18F-sodium fluoride PET/CT, 99mTc-labelled 
diphosphonate SPECT/CT, and planar bone scintigraphy for diagnosis of bone 
metastases in newly diagnosed, high risk prostate cancer. 
Randi F. Fonager, Helle D. Zacho, Niels C. Langkilde, Joan Fledelius, June A. 
Ejlersen, Christian Haarmark, Helle W. Hendel, Mine Benedicte Lange, Mads R. 
Jochumsen, Jesper C. Mortensen, and Lars J. Petersen. 
Manuscript under revision. 
Summary 
In a completely STARD-compliant DTA study, the diagnostic performance of 
NaF PET/CT, SPECT/CT and BS was compared in 37 newly diagnosed high-risk PCa 
patients (PSA ≥ 50 ng/mL). The prevalence of bone metastases in this study was 73%. 
More than 10 bone metastases were found by at least one imaging modality in 74% 
of patients. NaF PET/CT and SPECT/CT numerically outperformed BS with regard 
to sensitivity, specificity, PPV and NPV. The sensitivities were 78% for BS, 89% for 
SPECT/CT, and 89% for NaF PET/CT, and the specificities were 90%, 100%, and 
90%, respectively. The PPVs for BS, SPECT/CT and NaF PET/CT were 96%, 100%, 
and 96%, and the NPVs were 60%, 77% and 75%, respectively. No statistically 
significant difference between the three imaging modalities was observed.  In addition 
to the dichotomous classification of images, the images were evaluated with an 
equivocal rating option. The proportion of equivocal results was low for all three 
imaging modalities but lowest for NaF PET/CT (5% vs 11% for SPECT/CT and BS). 
In conclusion, all three imaging modalities showed high sensitivity and specificity. 
NaF PET/CT and SPECT/CT showed numerically improved, but not statistically 
superior, sensitivity compared with BS in this limited and selected patient cohort. In 
conclusion, SPECT/CT and NaF PET/CT can be used for the diagnosis of bone 
metastases on an equal level as BS.  
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 PAPER 3 
Observer agreement of treatment responses on planar bone scintigraphy in 
prostate cancer patients: importance of the lesion assessment method. 
Randi F. Fonager, Helle D. Zacho, Signe Albertsen, Joan Fledelius, June A. Ejlersen, 
Mette H. Christensen, Ramune Aleksyniene, José A. Biurrun Manresa, and Lars J. 
Petersen.  
Nucl Med Commun. 2017 Mar;38(3):215-221. (103) 
DOI: 10.1097/MNM.0000000000000643. 
Summary 
The observer agreement for treatment response assessment on BS was investigated in 
63 paired BS from 55 patients. Treatment response was assessed by three different 
methods: 1) Standard clinical assessment; 2) MD Anderson criteria for bone response; 
and 3) PCWG-2 criteria. Furthermore, observer agreement for the presence of bone 
metastases and number of bone metastases at baseline was investigated. This study 
showed that the observer agreement for treatment response assessment was highest 
when using the PCWG-2 criteria, which showed substantial to almost perfect 
agreement (Cohen’s kappa 0.84, 95% CI: 0.69–0.99).  When using standard clinical 
assessment, observer agreement was moderate (Cohen’s kappa 0.52, 
95% CI: 0.36-0.69). Moderate agreement was also found for the MD Anderson 
criteria (Cohen’s kappa 0.60, 95% CI: 0.44–0.77). Evaluation of baseline images for 
the presence of bone metastases showed almost perfect agreement (Cohen’s kappa 
0.94, 95% CI: 0.82-1.00). There was a large variation for lesion counting at the patient 
level. The difference in lesion count from one reader to another could be as high as 
±15 lesions depending on the skeletal region. This variation seemed to increase with 
an increasing number of lesions. In conclusion, response evaluation by individual 
counting of lesions on baseline and follow-up images cannot be recommended. The 
use of strict criteria, such as the PCWG-2 criteria, for assessment of treatment 
response evaluation by BS is therefore recommended (103).  
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 PAPER 4 
Prospective, comparative study of 18F-sodium fluoride PET/CT and planar bone 
scintigraphy for treatment response in prostate cancer. 
Randi F. Fonager, Helle D. Zacho, Niels C. Langkilde, Joan Fledelius, June A. 
Ejlersen, Helle W. Hendel, Christian Haarmark, Mette Moe, Jesper C. Mortensen, 
Mads R. Jochumsen and Lars J. Petersen 
Manuscript in preparation 
Summary 
In this study, the agreement between NaF PET/CT and BS for treatment response 
assessment by the PCWG criteria was investigated in PCa patients undergoing various 
palliative anti-cancer treatments at different stages of PCa. Furthermore, the 
concordance between imaging (NaF PET/CT and BS), biochemical (PSA) and clinical 
response was evaluated. There was no statistically significant difference in the 
proportion of patients showing PD on BS vs NaF PET/CT (p=0.18). Analysis by 
Cohen’s kappa showed moderate agreement between BS and NaF PET/CT for 
classification of PD vs non-PD (Cohen’s kappa: 0.53). Crude agreement between 
NaF PET/CT and BS for assessment of treatment response in bone from baseline to 
last follow-up scan was 86%. There was a trend that with more advancing PCa, crude 
agreement decreased, i.e., crude agreement was 89% for ADT, 88% for NGH, and 
80% for chemotherapy. When considering all intermediate scans and hence the 
time point for detection of PD, crude agreement decreased even further for NGH and 
chemotherapy: 75% and 70%, respectively. Most often, BS detected PD when 
NaF PET/CT did not, or BS detected PD on an earlier scan compared with 
NaF PET/CT. There were no statistically significant differences between the 
proportions of patients showing PD on BS and NaF PET/CT compared with PSA and 
clinical progression. Further studies are needed to investigate the use of NaF PET/CT 
for response monitoring of bone metastases in PCa and validation of NaF PET/CT for 
response assessment is necessary before this modality can be recommend for this 
purpose. 
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CHAPTER 5. DISCUSSION  
The overall aim of this PhD thesis was to evaluate BS, SPECT/CT and NaF PET/CT 
for diagnosis and monitoring of bone metastases in PCa. More specifically, the aim 
was to compare BS, SPECT/CT and NaF PET/CT for diagnosis of bone metastases in 
PCa (Study I), to evaluate observer agreement for evaluation of treatment responses 
on by three different methods for classification of response (Study II), and to compare 
BS and NaF PET/CT for monitoring of bone metastases in PCa (Study III).  
Diagnostic performance  
Diagnosis of bone metastases is crucial for PCa patient management. It is therefore 
extremely important that diagnostic tests have a sufficiently high sensitivity to detect 
even small bone metastases and hence a low number of false negative results. Similar 
to previous DTA studies (Table 2) (31, 32, 37-40), the results of Study I showed a 
high sensitivity for all three imaging modalities. On a patient level, the sensitivity of 
SPECT/CT and NaF PET/CT numerically outperformed the sensitivity of BS (89% 
and 89% vs 78%, respectively). This was expected due to the inherent improved image 
quality of the latter imaging modalities, i.e., three-dimensional images, CT for 
attenuation correction and anatomical co-localisation, the improved spatial resolution 
of PET/CT, and the higher target-to-background ratio gained with NaF PET/CT.  
The specificity of a diagnostic test is likewise of great importance. The specificity 
reflects the proportion of patients who are correctly identified as not having the 
disease, i.e., a high specificity reflects a low number of false positive results. The 
results of Study I showed that the specificity of NaF PET/CT was equal to that of BS 
(90%). This was in contrast to other studies, which have mostly demonstrated 
improved specificities of NaF PET/CT over BS (Table 2) (50, 51, 56-59). An even 
higher specificity was demonstrated by SPECT/CT (100%). The high specificity of 
BS in Study I, compared with previous studies, can in part be ascribed to the low 
number of patients without bone metastases in this study. However, it can also be 
explained by the experience of the expert readers who had more than 10 years of 
experience with BS reading starting before SPECT/CT became available as an add-on 
to BS. Therefore, these readers are likely to provide confident and unequivocal 
answers to BS.  
The rationale for conducting this DTA study was the lack of properly designed large 
studies that adequately demonstrate the diagnostic performance of SPECT/CT and 
NaF PET/CT. Such evidence is needed for clinical guidelines to include these imaging 
modalities as options for diagnosis of bone metastases in PCa. Even if Study I did not 
achieve the goal of 114 evaluable patients, this study was large among comparable 
studies, and it was conducted with stringent procedures in accordance with the 
STARD guideline for DTA studies. The major challenge with DTA studies in imaging 
has been the lack of a proper reference standard. It must be realised, though, that 
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without histological verification of all potential bone metastases, a single, 
unambiguous gold standard is utopian (68, 69). Thus, a reference standard based on 
the findings on the index test as a guide for determining the final diagnosis and a 
well-documented stringent procedure, as in Study I, can be considered sufficient to 
determine the final diagnosis. 
The diagnostic performance of BS, SPECT/CT and NaF PET/CT would most likely 
be different in an unselected population of newly diagnosed PCa patients or patients 
with recurrent disease following radical prostatectomy. However, a 
metastasis-enriched population was selected in Study I to optimize the sample size 
and statistical power (102). Study I was planned to include a high number of patients, 
which in combination with a methodologically sound design should have been able to 
provide firm evidence of the equal or superior diagnostic performances of SPECT/CT 
and NaF PET/CT for the diagnosis of bone metastases. Study I was prematurely 
ceased due to the realisation that recruitment of 114 patients was unlikely to be 
achieved within a realistic timeframe. Although Study I was large among similar 
studies, the power was limited due to the small number of patients in the study (50, 
51, 56-58, 60, 91). The impaired recruitment in Study I could in part be ascribed to 
the decrease in the proportion of newly diagnosed patients with high-risk PCa that has 
occurred during the past few decades (3, 109, 110). Furthermore, it is known that 
high-risk patients are likely to show symptoms of morbidity (10, 11, 111), which may 
make patients reluctant to participate in studies that require additional procedures.  
SPECT/CT is generally associated with a long acquisition time, thus causing 
additional discomfort to the patient. Recently, it was demonstrated that when using 
SPECT/CT for assessment of inconclusive bone lesions on BS the acquisition time of 
SPECT/CT can be reduced to as little as three minutes without compromising the 
diagnostic confidence of the examination (112). Thus, the discomfort of add-on 
SPECT/CT is notably reduced. This supports the use of SPECT/CT as an add-on to 
BS to gain an increased specificity of the examination. NaF PET/CT might be more 
comfortable for patients because the waiting time from injection of the tracer to the 
scan is shorter compared with BS (30-60 min vs 2-4 h for BS) and additionally 
NaF PET/CT has a faster acquisition time. 
As mentioned above, Study I included the results of the index tests in the 
determination of a final diagnosis, thus causing a slight risk of bias with circular 
reasoning in the final decision making. However, as mentioned, it can be argued that 
without the results of the index test as a guide for final decision making, a firm 
reference standard is difficult to obtain in imaging studies, even if guidelines for DTA 
studies, such as STARD, recommend otherwise (71). Aside from this, a major strength 
of Study I was the strict methodology, which was in complete compliance with the 
STARD recommendations. Therefore, even in the absence of a single, large DTA 
study with a high level of evidence that shows the improved diagnostic performance 
of SPECT/CT and NaF PET/CT over BS, it can be argued that the existing body of 
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evidence and the results of Study I provide sufficient evidence of this. SPECT/CT and 
NaF PET/CT can be considered as equal to BS for diagnostic purposes in PCa, and 
clinical guidelines should embed these imaging modalities for bone metastases 
staging in PCa with equal recommendations as those for BS.  
Treatment response assessment 
Assessment of treatment responses in bone is, as previously mentioned, an important 
aspect of patient management both in daily clinical practice and in clinical trials. Just 
as for the diagnosis of bone metastases, clinical guidelines and the PCWG recommend 
the use of BS for treatment response assessment in PCa. The methods for classifying 
responses have varied, and different response assessment methods have been 
presented. In addition, a high level of agreement between readers for response 
classification is extremely important, since progression on BS often is a determining 
factor for ceasing or continuing a treatment or investigational drug. However, 
observer agreement has not been investigated in the assessment of treatment responses 
in bone metastases from PCa.  
The results of Study II showed that inter-observer agreement according to Cohen’s 
kappa for bone response assessment was substantial/almost perfect when using the 
PCWG-2 criteria (Cohen’s kappa: 0.84). Agreement was moderate when using 
standard clinical assessment, as per daily clinical routine (Cohen’s kappa: 0.52), or 
the MD Anderson criteria (Cohen’s kappa: 0.60) (103). Standard clinical assessment 
and the MD Anderson criteria both have more response categories than PCWG-2, 
which by definition is associated with lower kappa values. However, agreement did 
not change when reclassifying these response classifications into non-PD vs PD. Thus, 
it is obvious that agreement for classification of response to treatment benefitted from 
the application of stringent criteria like the PCWG-2 (103). The results of Study II 
were consistent with the few existing studies on observer agreement for treatment 
response assessment in bone (93, 98).  
There is no general consensus on how to report treatment responses in clinical 
practice, but the results of Study II suggest that a uniform approach using stringent 
criteria will be beneficial for patient management by providing the most consistent 
results. Therefore, strict criteria should be used both in clinical trials and in clinical 
practice for treatment response assessment of bone metastases in PCa (103). The study 
population in Study II was mixed and included patients undergoing different 
anti-cancer treatments and the small study population did not allow for subgroup 
analysis of variations in inter-observer agreement depending on disease state or 
treatment (103). This could have been an interesting perspective, as it has the potential 
to influence the results of future studies and recommendations for the use of response 
classification methods. Nonetheless, the results of Study II did demonstrate a 
substantial to almost perfect inter-observer agreement when using the PCWG criteria, 
and the PCWG criteria are becoming widely accepted for the evaluation of bone 
metastases treatment response in clinical trials (103, 113). This is well supported by 
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the fact that progression on BS according to the PCWG-2 criteria is associated with 
impaired survival (87). Overall, this suggests, that the PCWG criteria might be the 
ideal choice for future application in clinical trials and daily clinical practice. 
The results from Study II on observer agreement clearly demonstrated that the PCWG 
criteria provided the most consistent results for evaluation of treatment response on 
BS (103). Based on these results, it was decided that the PCWG criteria should be 
used in Study III and in an exploratory setting, Study III prospectively compared the 
concordance between BS and NaF PET/CT for treatment response assessment in PCa. 
As mentioned, NaF PET/CT is not currently included in the clinical guidelines for the 
diagnosis or monitoring of bone metastases. The 2010 guideline from the Society of 
Nuclear Medicine stated that the role of NaF PET/CT is to be determined (46), while 
the 2015 European Association of Nuclear Medicine procedure guideline for NaF 
PET/CT recommended the use of NaF PET/CT for both diagnoses of bone metastases 
and for evaluation of treatment responses in bone metastases (43). However, no 
studies have directly compared the use of BS and NaF PET/CT for treatment response 
assessment in bone metastases.  
The results of Study III showed that there are some non-statistically significant 
variations in response classification between BS and NaF PET/CT and in the timing 
of progression occurrence. Agreement between BS and NaF PET/CT was moderate 
for the classification of PD/non-PD from baseline to last follow-up scan when using 
the PCWG criteria (Cohen’s kappa 0.53). In most cases where BS and NaF PET/CT 
showed discordance, BS detected PD when NaF PET/CT did not, or BS detected PD 
at an earlier time-point than NaF PET/CT, e.g., BS showed PD on the first follow-up 
scan while NaF PET/CT did not detect PD until the second follow-up scan. There was 
a trend that crude agreement declined with more advanced stages of PCa, i.e., CRPC 
for which the PCWG criteria were developed. This trend was even more evident when 
all individual scans were taken into consideration i.e., first, second and sometimes 
third follow-up scan. It is commonly known that NaF PET/CT detects a higher number 
of bone metastases than BS (56, 59). The discordance between BS and NaF PET/CT 
might therefore, in some cases be due to the appearance of new lesions on follow-up 
BS that were already visible on baseline NaF PET/CT, thus accounting for the 
classification of PD on BS but not on NaF PET/CT.  
When using standard clinical assessment to determine bone response, overall crude 
agreement between BS and NaF PET/CT from baseline to last follow-up scan was 
lower than when using the PCWG criteria, this was expected since standard clinical 
assessment has more response categories than the PCWG criteria (Table 3). Like for 
the PCWG criteria, standard clinical assessment also demonstrated decreased 
agreement with advancing PCa stages.  
Previous studies that have investigated treatment response on NaF PET/CT have 
focused on post-treatment changes in SUV inspired by the PERCIST criteria (99-101). 
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However, there is no universally agreed-upon reference level for changes in SUV that 
is considered significant, and no studies have investigated the impact of SUV changes 
on patient management. Other methods for quantification of NaF PET/CT have 
recently been presented (114, 115). Quantitative methods for evaluation of treatment 
response on NaF PET/CT are interesting, especially if small and clinically significant 
changes can be detected early during treatment. However, quantitative evaluation of 
NaF PET/CT remains under investigation and this was beyond the scope of this PhD 
thesis.  
Study III was limited by the small number of patients, and this precluded formal 
statistical subgroup analysis of the individual treatment groups. Sub-group analyses 
would have been interesting in light of the trend that crude agreement between BS and 
NaF PET/CT decreased with advancing PCa stages, i.e., CRPC patients, especially 
those receiving chemotherapy. Larger studies are encouraged to show variations for 
different anti-cancer treatments as this might be critical for the validation of 
NaF PET/CT for bone response assessment, especially when using the PCWG criteria. 
Clinical guidelines (5, 6) and PCWG-3 (24) emphasize that NaF PET/CT should be 
validated for bone response assessment before it can be recommended along with BS. 
This is supported by the results of Study III, which showed that there were some 
variations in the classification of bone response between BS and NaF PET/CT. The 
results of Study II demonstrated a high level of agreement between readers for 
evaluation of bone response on BS by the PCWG criteria (103) and it has previously 
been demonstrated that PD on BS, when assessed by the PCWG criteria, is associated 
with impaired OS (87). Therefore, recent recommendations of BS for bone response 
evaluation in PCa by PCWG-3 (24) and clinical guidelines (5, 6) are well 
substantiated. Combined, this indicates a need for further investigation of bone 
response assessment by NaF PET/CT. This is relevant both when assessing images on 
a visual basis, like in Study III, as well as when using quantitative methods for 
assessment of changes, such as SUV. In addition, even though a change in 
management was reported in up to 53% of PCa patients following NaF PET/CT (47) 
, a proper investigation is necessary to determine whether bone response assessment 
by NaF PET/CT is associated with improved patient outcome.  
In conclusion, larger studies on NaF PET/CT for response assessment with a focus on 
patient outcome are encouraged, and until the results of NaF PET/CT have been 
validated, BS should be retained as the primary modality for bone response 
assessment. 
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CHAPTER 6. CONCLUSIONS  
SPECT/CT and NaF PET/CT show apparent improved diagnostic performance over 
BS. If feasible, both SPECT/CT and NaF PET/CT can be used as modalities equal to 
BS for the detection of bone metastases in PCa, and they should be adopted in future 
clinical guidelines.  
Observer agreement on bone response shows the least variation when using stringent 
criteria that distinguish only non-PD from PD and the use of stringent criteria should 
be encouraged for treatment response evaluation in clinical trials as well as in clinical 
practice. The PCWG criteria will likely become the standard approach in the future. 
Treatment response assessment by NaF PET/CT should be investigated further to 
determine the association with patient outcomes, e.g., OS and changes in patient 
management. The recommendations for the use of BS for bone response assessment 
are well substantiated, and until NaF PET/CT has been validated for bone response 
assessment, NaF PET/CT cannot be recommended for bone metastases monitoring in 
PCa.   
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